ProKidney (NASDAQ:PROK – Get Free Report) and uniQure (NASDAQ:QURE – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.
Profitability
This table compares ProKidney and uniQure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -10,288.39% | N/A | -27.39% |
| uniQure | -1,350.73% | -111.96% | -29.01% |
Valuation & Earnings
This table compares ProKidney and uniQure”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $890,000.00 | 499.34 | -$68.99 million | ($0.55) | -2.67 |
| uniQure | $16.10 million | 90.35 | -$198.97 million | ($4.01) | -5.23 |
ProKidney has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
51.6% of ProKidney shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for ProKidney and uniQure, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 1 | 0 | 1 | 1 | 2.67 |
| uniQure | 1 | 3 | 11 | 1 | 2.75 |
ProKidney presently has a consensus price target of $12.00, indicating a potential upside of 716.33%. uniQure has a consensus price target of $53.73, indicating a potential upside of 156.21%. Given ProKidney’s higher probable upside, equities research analysts clearly believe ProKidney is more favorable than uniQure.
Volatility & Risk
ProKidney has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, uniQure has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Summary
ProKidney beats uniQure on 9 of the 14 factors compared between the two stocks.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
